Le Lézard
Classified in: Health
Subject: v

Healthcare Special Opportunities Fund Announces September 2019 Quarterly Distribution


NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

TORONTO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- (TSX: MDS.UN) ? LDIC Inc. (the "Manager"), the manager of Healthcare Special Opportunities Fund (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.06103 per Class A unit and US$0.06046 per Class U unit. The distribution will be paid on or before October 15, 2019 to unitholders of record on September 30, 2019.

For further information please contact:

Michael B. Decter
President & Chief Executive Officer
LDIC Inc.
Tel: (416) 362-4141
Email: [email protected]
Website: www.ldic.ca


These press releases may also interest you

at 00:05
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
Few small SUVs excel in new IIHS front crash prevention test
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential expands globally to Oceania, Asia and the Gulf
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research Statement on Co-Founder and Chairman Dr. Stephen Harrison
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

More news about Health...


News published on and distributed by: